This issue, focusing on Breast Cancer, includes topics such as: Radiation Therapy for DCIS, Axillary dissection, Pathology in the age of personalized breast cancer treatment:, Clinical implications for breast cancer subsets defined by molecular diagnostics, Management of CNS Metastases in Breast Cancer, Endocrine therapy for advanced breast cancer, Targeting the PI3K pathway in breast cancer, Treating the Older Breast Cancer Patient, Adjuvant chemotherapy in the age of targeted treatment, and Novel radiotherapy approaches for early breast cancer

Molecular pathology has significantly matured over the past decade to establish itself as a discipline in its own right. Patient diagnosis, prognosis, management and care have been influenced by molecular pathology testing algorithms on a global scale. Whether it pertains to carrier status of deleterious genes, diagnosis by molecular techniques, assessment of appropriate remission post treatment, parentage or forensics testing - molecular pathology continues to increase its presence and influence in the diagnostic laboratory armamentarium. Furthermore, intellectualization and proprietization of molecular pathology with respect to the discovery of new genes and or new techniques continues to pose new challenges of test ownership, legalities, liabilities, widespread acceptance and utility. This issue of Laboratory Clinics seeks to provide selective state of the art understanding of molecular pathology with respect to its relationship to key pathology disciplines as well as the current challenges and promise for the future

This issue focuses on Sarcoma in areas such as: Gastrointestinal Stromal Tumors: Risk assessment and adjuvant therapy, Gastrointestinal Stromal Tumors: Management of metastatic disease and emerging therapies, Liposarcoma, Leiomyosarcoma, Update in treatment and targets in cartilage and bone tumors, Update in treatment and targets in Ewing sarcoma, Angiosarcoma and Epithelioid Hemangioendothelioma, Emerging therapies for sarcoma, and Treatment of localized sarcomas.

This issue of Hematology/Oncology Clinics is guest edited by Dr. A. Koneti Rao and focuses on Disorder of the Platelets. Article titles include: Mechanisms of Platelet Activation and Inhibition, Testing Platelet Function, Clinical Implications of Platelet Genomics and Proteomics, Congenital Thrombocytopenias, Immune Thrombocytopenias, Heparin Induced Thrombocytopenia, and Functional defects: Chronic granulomatous disease (CGD) and beyond

Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of personalized cancer therapy is now growing rapidly, and the progress being made will result in significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. This book, written by acknowledged experts, discusses in detail the most recent developments in targeted cancer therapy using small molecules. A wide range of small molecules is covered, including, in addition to tyrosine kinase inhibitors, mTOR, proteasome, and multikinase inhibitors, among others. For each molecule, aspects such as chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed.

This issue focuses on three disease sections: Diabetes, Hematology and Coagulation, and covers diagnostic and management issues during pregnancy of selected topics in each section. The chapters cover new concepts, evolving management and important impacts on the mother and unborn child.

This issue of Hematology/Oncology Clinics is edited by Dr. Jennifer Brown and focuses on Chronic Lymphocytic Leukemia. Article topics include: What Have Recent Genomic Advances Taught us About CLL?, Biology of CLL in Different Microenvironments, What is the Significance of Stereotyped BCRs in CLL?, Understanding Immunodeficiency in CLL, MBL vs CLL: How Important is the Distinction?, Risk Stratification of CLL in 2012, Minimal Residual Disease Measurement in CLL, The BTK Inhibitor PCI-32765 in CLL, and Evolving Role of Stem Cell Transplantation in CLL

This issue of Hematology/Oncology Clinics is guest edited by Dr. Christoph Klein and focuses on the topic of Neutropenia. Article titles include: Homeostasis and migration of neutrophil granulocytes, Granulocyte-colony Stimulating Factor (G-CSF) receptor signaling, New Granulocyte-colony Stimulating Factor (G-CSF) Receptor Signaling Pathways, Neutrophil elastase (ELANE) - Genetics and Pathophysiology, Autosomal recessive variants of Severe congenital neutropenia (SCN), Leukocyte Adhesion Deficiency (LAD), and Genotype-phenotype correlations in Severe congenital neutropenia (S

"The HDL Handbook: Biological Functions to Clinical Implications" brings laboratory research in HDL from bench to bedside in this needed resource for researchers and clinicians studying cholesterol, lipids, epidemiology, biochemistry, molecular medicine, and pathophysiology of cardiovascular diseases. In addition, researchers and clinicians working with an aging population, corporate researchers, post-doctorates; medical students and graduate students will find this publication usefulbecause the scope of coverage includes basic science, genetics, epidemiology, and treatment of HDL cholesterol as well as potential targets to modify HDL cholesterol.
Provides bench-to-bedside coverage of HDL with thorough coverage of basic science, genetics, epidemiology, and treatment Presents a complete update with six new chapters on the latest advances in HDL cholesterol research with international perspective New chapters on proteomics, clinical impact of LCAT in HDL metabolism, and an in-depth discussion of potential targets to modify HDL provide a translational reference for clinicians"

Typically, manuals of pediatric hematology-oncology are written by specialists from high-income countries, and usually target an audience with a sub-specialist level of training, often assisted by cutting-edge diagnostic and treatment facilities. However, approximately 80% of new cases of cancer in children appear in mid- and low-income countries. Almost invariably, general practitioners or general pediatricians without special training in oncology will look after children with malignancies who enter the health care system in these countries. The diagnostic facilities are usually limited, as are the treatment options. The survival figures in these conditions are somewhere below 20%, while in high-income countries they are in the range of 80% for many childhood cancers. Pediatric Hematology-Oncology in Countries with Limited Resources is the only book of its kind to provide specific guidance applicable to limited resource settings and builds up from the foundation of general practitioner or general pediatrician competence. Written and edited by leaders in the field, this manual educates physicians on the essential components of the discipline, filtered through the experience of specialists from developing countries, with immediate applicability in the specific healthcare environment in these countries.

2014 BMA Medical Book Awards Highly Commended in Internal Medicine category! This textbook on haematology in the Illustrated Colour Text series is suitable for medical students, junior doctors and others needing a concise and practical introduction to the subject. Concise and manageable coverage of the major blood diseases and their treatment. Does not overload the reader with science, unlike some competing books. Focus is on the haematology patient and on the practical aspects of the subject. Makes use of the attractive features of the ICT series - double page spreads, lots of colour illustrations, summary boxes. Updating to take account of recenty developments in stem cell biology. Increased emphasis on genomic and proteomic techniques in the diagnosis of haematological malignancy. Use of new imaging techniques including MRI and PET. Description of advances in treatment of leukaemia and lymphoma and in diagnosis and management of patients with thrombophilia and venous thrombosis. Development of new antimicrobial agents in management of immunosuppressed patients with infection. New double page spread on palliative care of patients with blood disorders. New illustrations.

Topics include: Clinical Predictors of Outcome in MPNs; Molecular pathogenesis of MPNs; Disordered signaling in MPNs; Role of TET2/ASXL1 in MPN Pathogenesis; Pathogenesis and treatment of systemic mastocytosis; Role of additional novel therapies in MPNs; Role of novel mutations in MPN pathogenesis and outcome; Role of JAK inhibitors in MPN treatment; Animal Models of MPNs; and Role of Germline Genetic Factors in MPN Pathogenesis.

Topics include: A Critical re-appraisal of Factor VIIa; Thrombocytopenia: Hit vs non-HIT causes; Transfusion Reactions: Newer concepts on the pathophysiology, incidence, treatment and prevention of TRALI; The utility of diagnostic scoring systems for DIC; Newer anticoagulants; Anemia in the ICU; The role of plasmapheresis in critical illness; The use of erythropoiesis stimulating agents in the ICU; and Coagulopathy in the ICU: DIC vs Liver disease. Is this distinction important?

Topics in this issue?include: Targeting IGF-1R; Tyrosine Kinase Inhibitors in Lung Cancer; Targeting mTOR; Targeting Hedgehog; Mitotic Inhibitors; Topoisomerase I Inhibitors; and New Strategies and Drugs Inhibiting Folate Pathways.

Topics for this issue will include: CLL: ? A Historical Perspective; Incidence & Epidemiology; Biology, Molecular Biology & Cytogenetics of CLL; What does the status of smatic hypermutations in IGVH genes tell us about the origin of CLL?; What does the status of ZAP-70 tell us about the biology of CLL?; and Approach to initial therapy: When to start therapy?

Dr. Talpaz has assembled top experts to write state-of-the art reviews on the management of chronic myelogenous leukemia. Some of the articles that will be of most interest include Selection of Therapy: Rational Decisions Based on Molecular Events; Is There a Potential Cure for CML in Current Therapies?; Hurdles Toward a Cure for CML: The CML Stem Cell; The CML Stem Cell in the Chronic and Advanced Disease; CML Disease Progression; Management of Ph+ ALL and CML Blast Crisis; BMT in CML in the Era of Targeted Therapy; Pharmacoeconomics: The Cost of Staying Alive; and The Significance of CML Prognostic Factors in the Era of Targeted Therapy.

Topics in this issue?include: Why does my patient have leukocytosis?; Why Is My Patient Neutropenic?; Does My Patient with a Serum Monoclonal Spike have Multiple Myeloma?; DVT and Pulmonary Embolism; Why Does My Patient Have Lymphadenopathy/Splenomegaly?; and Why Does My Patient have Thrombocytopenia?

Topics?in this issue?include: Genetic Risk and Gynecologic Cancer; Current Management of Preinvasive Cervical Neoplasia; Current Surgical Management of Cervical Neoplasia; Current Surgical Management of Ovarian Cancer; Current Management of Trophoblastic Disease; and New Developments in Radiation Management and Gynecologic Cancers.

Thalassemia is discussed comprehensively by the authors in this issue.? Topics discussed include the population genetics and dynamimcs of thalassemia, alpha thalassemia, HbE/beta thalassemia, management of iron overload in thalassemia syndromes, allogeneic cellular gene therapy for hemoglobinopathies, cord blood transplantation for beta thalassemia major, and gene therapy for hemoglobin disorders.

This textbook is written by a renowned haematologist with more than 30 years of experience in teaching haematology to medical students and whose pedagogical and writing skills are widely admired within the field. Following closely the current curriculum of Imperial College London, medical students, trainee nurses and biomedical science students from other institutions will find the textbook equally suitable, since it includes the core student haematology curriculum as recommended by the Royal College of Pathologists and the British Society of Haematology expert group. This text will be equally suitable for students outside the UK.

The textbook takes a useful, practical approach, incorporating self-evaluation questions and learning objectives that give students not only the information needed to understand the topic but also clear indications on the core knowledge that students are required to know in order to progress within the field of haematology.

The understanding of hemostasis physiology has been considerably advanced by models of kinetics and by the complicated interplay of cells and soluble coagulation factors. How this physiology is currently, or will eventually, be reflected in clinical laboratory testing is the subject of this monograph; this information is key for laboratorians to implement physiologic concepts into practical data and for clinicians to understand the basis of and therefore correctly treat hemostatic disease. Many thousands of patients present with bleeding disorders or bleeding complications of other diseases, and millions of individuals suffer the morbidity and mortality of thromboembolic complications. How laboratory testing confronts the challenge of predicting different hemostatic risks and guiding therapy is the critical subtext of the chapters in this monograph. New developments in hemostasis physiology have identified thrombin as an important, if not central, coordinator of hemostatic function and thus a target for measurement to assess hemostatic function and risk. Whether such measurements as endogenous thrombin potential or thromboelastography will accurately predict and/or quantitate global hemostatic function is an important question. Modeling the clinical risks of bleeding or thromboembolism currently uses the laboratory presence or absence of particular risk factors, but our clinical understanding of risk appears to more closely approximate a dynamic model, even within individual patients. Therefore, testing for platelet dysfunction or comprehending the functional implications of a lupus anticoagulant may rely on our evolving comprehension of hemostasis phyisology and perhaps require more sophisticated interpretation of clinical predictors of hemostatic risk. This monograph aims to shed some light in these areas and promote investigation of such key hemostasis issues.